Ligand Pharmaceuticals Incorporated
$5.33B- Market cap
- $5.69B
- Debt
- +$374.08M
- Cash
- −$733.52M
Capital structure 94% equity / 6% debt · EV / Revenue 19.90x · EV / EBITDA 33.28x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price vs ACAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · ACAD FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.90x · EV / EBITDA 33.28x
Capital structure 94% equity / 6% debt · EV / Revenue 4.63x · EV / EBITDA 32.90x
LGND carries the larger enterprise value at $5.33B against $4.96B; ACAD trades on the lower EV / Revenue multiple (4.63x vs 19.90x); ACAD on the lower EV / EBITDA (32.90x vs 33.28x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
0.25x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
0.85x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$177.70M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
SUPERNUS PHARMACEUTICALS, INC.
LGND vs SUPN
Sage Therapeutics, Inc.
LGND vs SAGE
Jazz Pharmaceuticals plc
LGND vs JAZZ
Alkermes plc.
LGND vs ALKS
Harmony Biosciences Holdings, Inc.
LGND vs HRMY
Krystal Biotech, Inc.
LGND vs KRYS
$374.08M
$306.51M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.